Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)

被引：34
|
作者：
Brooks, Carl A. [1 ]
Barton, Linda S. [1 ]
Behm, David J. [1 ]
Eidam, Hilary S. [1 ]
Fox, Ryan M. [1 ]
Hammond, Marlys [1 ]
Hoang, Tram H. [1 ]
Holt, Dennis A. [1 ]
Hilfiker, Mark A. [1 ]
Lawhorn, Brian G. [1 ]
Patterson, Jaclyn R. [1 ]
Stoy, Patrick [1 ]
Roethke, Theresa J. [1 ]
Ye, Guosen [1 ]
Zhao, Steve [1 ]
Thorneloe, Kevin S. [1 ]
Goodman, Krista B. [1 ]
Cheung, Mui [1 ]
机构：
[1] GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metab Pathways & Cardiovasc Therapeut Area, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 08期
关键词：
GSK2798745; TRPV4; congestive heart failure; conformational bias; volume of distribution; INTRAVENOUS PHARMACOKINETIC PARAMETERS; QUALITATIVE EVALUATION; CATION CHANNEL; ACTIVATION; IDENTIFICATION; EXTRAPOLATION; PROTEIN; HUMANS; MONKEY; SERIES;
D O I：
10.1021/acsmedchemlett.9b00274
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
GSK2798745, a clinical candidate, was identified as an inhibitor of the transient receptor potential vanilloid 4 (TRPV4) ion channel for the treatment of pulmonary edema associated with congestive heart failure. We discuss the lead optimization of this novel spirocarbamate series and specifically focus on our strategies and solutions for achieving desirable potency, rat pharmacokinetics, and physicochemical properties. We highlight the use of conformational bias to deliver potency and optimization of volume of distribution and unbound clearance to enable desirable in vivo mean residence times.
引用
收藏
页码：1228 / 1233
页数：11
相关论文
共 50 条
  • [1] Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4)
    Brooks, Carl A.
    Barton, Linda S.
    Behm, David J.
    Brnardic, Edward J.
    Costell, Melissa H.
    Holt, Dennis A.
    Jolivette, Larry J.
    Matthews, Jay M.
    McAtee, John J.
    McCleland, Brent W.
    Patterson, Jaclyn R.
    Pero, Joseph E.
    Rivero, Ralph A.
    Roethke, Theresa J.
    Sanchez, Robert M.
    Shenje, Raynold
    Terrell, Lamont R.
    Lawhorn, Brian G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 9270 - 9280
  • [2] Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4) Mitigates Seizures
    Zeng, Meng-liu
    Cheng, Jing-jing
    Kong, Shuo
    Yang, Xing-liang
    Jia, Xiang-lei
    Cheng, Xue-lei
    Chen, Ling
    He, Fang-gang
    Liu, Yu-min
    Fan, Yuan-teng
    Gongga, Lanzi
    Chen, Tao-xiang
    Liu, Wan-hong
    He, Xiao-hua
    Peng, Bi-wen
    NEUROTHERAPEUTICS, 2022, 19 (02) : 660 - 681
  • [3] Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4) Mitigates Seizures
    Meng-liu Zeng
    Jing-jing Cheng
    Shuo Kong
    Xing-liang Yang
    Xiang-lei Jia
    Xue-lei Cheng
    Ling Chen
    Fang-gang He
    Yu-min Liu
    Yuan-teng Fan
    Lanzi Gongga
    Tao-xiang Chen
    Wan-hong Liu
    Xiao-hua He
    Bi-wen Peng
    Neurotherapeutics, 2022, 19 : 660 - 681
  • [4] Identification, Synthesis, and Characterization of a Major Circulating Human Metabolite of TRPV4 Antagonist GSK2798745
    Pero, Joseph E.
    McAtee, John J.
    Behm, David J.
    Briand, Jacques
    Graczyk-Millbrandt, Grazyna
    Erhard, Karl
    Roberts, Andrew D.
    Rivero, Ralph A.
    Holt, Dennis A.
    Lawhorn, Brian G.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (09): : 1498 - 1502
  • [5] A SEGMENTAL LPS CHALLENGE STUDY TO INVESTIGATE THE PHARMACODYNAMICS OF A TRPV4 ANTAGONIST (GSK2798745) IN HEALTHY PARTICIPANTS
    Mole, S.
    Harry, A.
    Fowler, A.
    Hotee, S.
    Warburton, J.
    Waite, S.
    Beerahee, M.
    Behm, D.
    Badorrek, P.
    Mueller, M.
    Faulenbach, C.
    Lazaar, A.
    Hohlfeld, J. M.
    THORAX, 2019, 74 : A153 - A153
  • [6] Transient receptor potential vanilloid 1 (TRPV1), TRPV4, and the kidney
    Kassmann, M.
    Harteneck, C.
    Zhu, Z.
    Nuernberg, B.
    Tepel, M.
    Gollasch, M.
    ACTA PHYSIOLOGICA, 2013, 207 (03) : 546 - 564
  • [7] The role of transient receptor potential vanilloid 4 (TRPV4) channels in atopic dermatitis
    Kosaka, K.
    Uchiyama, A.
    Amalia, S. N.
    Inoue, Y.
    Ishikawa, M.
    Yokoyama, Y.
    Ogino, S.
    Hosoi, M.
    Torii, R.
    Motegi, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S17 - S17
  • [8] Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4)
    Brnardic, Edward J.
    Ye, Guosen
    Brooks, Carl
    Donatelli, Carla
    Barton, Linda
    McAtee, Jeff
    Sanchez, Robert M.
    Shu, Arthur
    Erhard, Karl
    Terrell, Lamont
    Graczyk-Millbrandt, Grazyna
    He, Yanan
    Costell, Melissa H.
    Behm, David J.
    Roethke, Theresa
    Stoy, Patrick
    Holt, Dennis A.
    Lawhorn, Brian G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (21) : 9738 - 9755
  • [9] The vanilloid transient receptor potential channel TRPV4: From structure to disease
    Everaerts, Wouter
    Nilius, Bernd
    Owsianik, Grzegorz
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2010, 103 (01): : 2 - 17
  • [10] Effect of TRPV4 Antagonist GSK2798745 on Chlorine Gas-Induced Acute Lung Injury in a Swine Model
    Vermillion, Meghan S.
    Saari, Nathan
    Bray, Mathieu
    Nelson, Andrew M.
    Bullard, Robert L.
    Rudolph, Karin
    Gigliotti, Andrew P.
    Brendler, Jeffrey
    Jantzi, Jacob
    Kuehl, Philip J.
    McDonald, Jacob D.
    Burgert, Mark E.
    Weber, Waylon
    Sucoloski, Scott
    Behm, David J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
12345